Jamshid Maddahi, MD
Cardiology · Los Angeles, CANPI 1154453769
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $54,378 of the $58,771 with a category attached, or 92.5%. GE HealthCare accounts for 94.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $45,848 and has fallen 97.9% since, to $970 in 2025. Among cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $374.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$56K
- Amgen$1K
- Johnson & Johnson$485
- Novartis$284
- Boehringer Ingelheim$278
- AstraZeneca$209
- plus $782 from 11 others
Across 13 payments — averaging $6774.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GE HealthCare$88K
What the payments were for
- Consulting fees$54,37893%
- Speaking & faculty fees$3001%
- Food & beverage$4,0927%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 15 | $55,583 |
| Amgen | 46 | $1,150 |
| Johnson & Johnson | 25 | $485 |
| Novartis | 11 | $284 |
| Boehringer Ingelheim | 11 | $278 |
| AstraZeneca | 9 | $209 |
| E.r. Squibb & Sons, L.L.C. | 11 | $197 |
| Novo Nordisk | 6 | $131 |
| Sanofi-aventis U.S. LLC | 5 | $112 |
| Pfizer | 3 | $82 |
| Azurity Pharmaceuticals, Inc. | 4 | $60 |
| Arbor Pharmaceuticals, Inc. | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Merck | 2 | $42 |
| Lilly USA, LLC | 1 | $29 |
| Gilead | 1 | $21 |
| Travere Therapeutics, Inc. | 2 | $1 |
How this compares
$58,771 in reported general payments places this provider in the 95th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 281 | $249,845 |
| EliquisApixaban | 268 | $237,156 |
| XareltoRivaroxaban | 63 | $71,289 |
| VascepaIcosapent Ethyl | 101 | $60,049 |
| JardianceEmpagliflozin | 36 | $46,649 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 87 | $36,978 |
| MultaqDronedarone Hcl | 30 | $35,884 |
| Praluent PenAlirocumab | 39 | $31,752 |
| JanuviaSitagliptin Phosphate | 30 | $28,944 |
| TrulicityDulaglutide | 25 | $28,403 |
| EntrestoSacubitril/Valsartan | 29 | $27,515 |
| EdarbiAzilsartan Medoxomil | 60 | $26,416 |
| OzempicSemaglutide | 16 | $23,943 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $19,079 |
| Repatha SyringeEvolocumab | 24 | $18,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $237,156268 claims |
| Johnson & JohnsonXarelto | $485 | $71,28963 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $53 | $63,394147 claims |
| MerckJanuvia, Janumet | $42 | $48,02349 claims |
| Boehringer IngelheimJardiance | $278 | $46,64936 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $29 | $39,97136 claims |
| Sanofi-aventis U.S. LLCMultaq | $112 | $35,88430 claims |
| NovartisEntresto | $284 | $27,51529 claims |
| Novo NordiskOzempic | $131 | $23,94316 claims |
| AstraZenecaFarxiga | $209 | $11,14212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 cardiology providers in California.
Other cardiology in Los Angeles
- Sanjay KaulLos Angeles$1.1M
- Hooman MadyoonLos Angeles$24K
- Andrew KimLos Angeles$5K
- Shawn ShahLos Angeles$3K
- Mark UrmanLos Angeles$1K
- Hiram PalmerLos Angeles$979
- Rene PackardLos Angeles$774
- Michael WongLos Angeles$510
- Norman LeporBeverly Hills$1.9M
- Ramtin AgahMountain View$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.